Bullish indicating open at $55-$60, IPO prices at $37
SAN DIEGO - Ainos, Inc. (NASDAQ:AIMD), a micro-cap technology company with a market capitalization of $9.7 million, has secured a three-year subscription-based order valued at $2.1 million with ASE Technology Holding Co., Ltd., the company announced Wednesday. According to InvestingPro data, this contract represents a significant opportunity for the company, which generated just $110,000 in revenue over the last twelve months.
The agreement involves deploying 1,400 AI Nose units across three of ASE’s manufacturing sites in Taiwan. This marks the first commercial application of Ainos’ AI-powered scent digitization platform in semiconductor manufacturing and represents the company’s second revenue-generating deployment following an earlier rollout in the senior care sector during the first quarter of 2025. The deal comes at a crucial time, as InvestingPro analysis shows the company has been rapidly burning through cash, with a negative free cash flow of $5.6 million in the last twelve months.
Under the agreement, Ainos will implement its SmellTech-as-a-Service model at ASE’s facilities in Kaohsiung, Zhongli, and SPIL. The technology aims to enhance process stability, support predictive maintenance, and increase operational safety through AI-powered scent intelligence.
"We’re executing with speed and precision," said Eddy Tsai, Chairman and CEO of Ainos, in the press release. "This initial deployment proves AI Nose’s real-world value."
The company also announced plans for pilot deployments at seven sites in Japan with robotics partner ugo, Inc., while advancing multi-site rollouts with Kenmec and Solomon in Taiwan.
The AI Nose platform combines MEMS sensor arrays with proprietary algorithms to detect scents at parts-per-billion sensitivity. The system converts analog scent data into what the company calls "Smell ID," which can be used for continuous monitoring, predictive analytics, and alerts.
According to data cited in the company statement, the global electronic nose market is projected to grow from $29.8 billion in 2025 to $76.5 billion by 2032, with industrial monitoring leading demand. Despite the market potential, InvestingPro analysis indicates challenging fundamentals for Ainos, with an overall Financial Health score rated as WEAK and a debt-to-equity ratio of 0.91. Subscribers to InvestingPro can access 6 additional key insights about Ainos’s financial position and growth prospects.
Ainos, which trades on the Nasdaq under the ticker AIMD, is headquartered in the United States and operates with partners across Taiwan and Japan. The stock has experienced significant volatility, with a beta of 2.21 and a recent one-week decline of nearly 11%, while trading at 0.74 times book value.
In other recent news, Ainos, Inc. reported a significant 412% year-over-year increase in Q1 revenue, marking its first revenue from AI Nose technology deployments in Japan’s senior care sector. The company has also completed a 1-for-5 stock consolidation, effective June 30, 2025, as part of its strategy to strengthen its capital structure and maintain its Nasdaq listing. This consolidation aims to attract institutional investors and reduce outstanding shares while maintaining shareholder ownership percentages. Additionally, Ainos has formed a strategic partnership with Taiwan-based Kenmec Mechanical Engineering Co., Ltd. to scale its AI Nose technology for industrial applications. Kenmec will receive a commercial license to deploy this technology in automation solutions, with plans to showcase their advancements at Automation Taipei 2025. Meanwhile, Ainos announced a collaboration with ugo, Inc. to deploy smell-sensing robots across seven industrial sites in Japan, enhancing operations in pharmaceutical manufacturing and other sectors. Furthermore, the company received regulatory approval in Taiwan to begin human clinical trials for its VELDONA oral interferon treatment, targeting HIV-related oral warts and primary Sjögren’s syndrome, with patient enrollment anticipated in the latter half of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.